ProCE Banner Activity

Podcast Pearls
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

PDF
Podcast Episodes
Download this PDF resource with summary points from a podcast episode featuring Sara Tinsley, PhD, APRN, AOCN, discussing the use of targeted therapies in patients with FLT3 or IDH1/2 mutated AML

Released: January 06, 2022

Expiration: January 05, 2023

No longer available for credit.

Share

Faculty

Sara Tinsley-Vance

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie

Faculty Disclosure

Primary Author

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Sara M. Tinsley, PhD, APRN, AOCN, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Incyte, and Taiho and fees for non-CME services from Astellas, Bristol-Myers Squibb, and Incyte.